^
    CANCER:

    Gallbladder Cancer





    Show legend
    Group by Gene:
    0
    Thymidylate synthase inhibitor
    capecitabine
    5-fluorouracil
    1
    DNA synthesis inhibitor
    gemcitabine
    2
    DNA synthesis inhibitor, Bcl2 inhibitor, Tubulin inhibitor
    cisplatin + gemcitabine + albumin-bound paclitaxel
    3
    HER2 inhibitor
    trastuzumab
    4
    PARP inhibitor
    olaparib
    PD1 inhibitor
    		5
    PD1 inhibitor
    pembrolizumab
    dostarlimab-gxly
    6
    FGFR inhibitor
    pemigatinib
    Debio 1347
    7
    PRMT5 inhibitor
    AMG 193
    MRTX1719
    8
    VEGF-A inhibitor
    bevacizumab
    9
    HER2 inhibitor, PD1 inhibitor
    trastuzumab + camrelizumab
    10
    ERK2 inhibitor, ERK1 inhibitor
    BVD-523
    11
    EGFR inhibitor
    erlotinib
    12
    ALK inhibitor
    crizotinib
    GC
    GemOx
    		13
    Chemotherapy
    GEM-CAP
    CAPOX
    XP
    FP
    14
    DNA synthesis inhibitor, DNA cross linking agent, Thymidylate synthase inhibitor
    5-fluorouracil + oxaliplatin
    15
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    trastuzumab + lapatinib
    16
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    neratinib
    17
    cRAF inhibitor, MEK inhibitor, BRAF inhibitor
    binimetinib + encorafenib
    18
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    No biomarker
    HER-2 amplification
    HER-2 positive
    HER-2 mutation
    HER-2 overexpression
    HER-2 S310F
    ERBB3 mutation
    ERBB3 amplification
    ERBB3 amplification + ERBB3 mutation
    PD-L1 expression
    FGFR mutation
    BRCA1 mutation
    BRCA1 S451Lfs*20
    FGFR fusion
    BRAF L485W
    BRAF D594N
    BRCA1 Q858
    TMB-L + ARID1A deletion + CDKN2A deletion + CDKN2B deletion + MTAP deletion + PIK3R1 N564D + NBN P81fs*23
    DCK positive
    MTAP deletion
    EGFR T790M
    TMB-H
    FGFR3-TACC3 fusion
    STK11 K262Sfs*25
    ATM S1905Ifs*25 + STK11 K262Sfs*25
    KRAS G12D
    MSI-H/dMMR
    MET amplification
    CDKN2A deletion
    CDKN2A mutation